rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Chemomab Therapeutics Ltd. - American Depositary Shares

CMMB · Nasdaq

Health CareBiotechnologyNot moving yet

CMMB stood above a rising 150-day average in 5 of the last 52 weekly readings, and has been out of that trend for the last 4 weeks. It is 35.4% below that average now. Biotechnology: 16% of its 561 stocks in an uptrend (−15 points in four weeks); Health Care: 26% (−10 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 4
Industry in uptrend
16% -15 in 4 wk
Insider buys, 12 months
$40K
Insider sales, 12 months
$13K
Officials’ trades on record
0
Institutions holding
13 (-2)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 5 of 52 weeks.

20 Apr – 19 Oct
17%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$11K$0$39KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months1
Sale orders, 12 months2
Buyers · sellers1 · 1
WhoDidSharesTraded
Neil Harris CohenDirectorsold1,000at $2.8028 Aug 2026filed 1 Sep 2026
Neil Harris CohenDirectorsold1,304at $2.8527 Aug 2026filed 1 Sep 2026
George Adi MorChief Executive Officerbought4,878at $2.0529 May 2026filed 1 Jun 2026
George Adi MorChief Executive Officerbought4,926at $2.0829 May 2026filed 1 Jun 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders13-2 on the quarter
New · exited1 · 3
Reported value$615K

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
CITADEL ADVISORS LLCadded · filed 14 Aug 202695,311$154K+31,129+48.5%
ADAR1 Capital Management, LLCunchanged · filed 14 Aug 202680,000$130K00.0%
KESTRA PRIVATE WEALTH SERVICES, LLCunchanged · filed 28 Jul 202661,710$100K00.0%
Ikarian Capital, LLCunchanged · filed 14 Aug 202651,793$84K00.0%
RHUMBLINE ADVISERSadded · filed 12 Aug 202630,529$49K+12,163+66.2%
XTX Topco Ltdreduced · filed 14 Aug 202615,987$26K-2,642−14.2%
Philadelphia Investment Partners, LLCadded · filed 14 Aug 202615,000$24K+6,800+82.9%
Lido Advisors, LLCnew · filed 7 Aug 202614,341$23K+14,341
BNP PARIBAS FINANCIAL MARKETSreduced · filed 13 Aug 20266,805$11K-1,620−19.2%
GAMMA Investing LLCreduced · filed 7 Jul 20264,740$7,679-2,839−37.5%
31 Mar 2023 – 30 Jun 2026
112232Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Neil Harris Cohen Company insiderDirector · last 28 Aug 20264 · 3
George Adi Mor Company insiderChief Executive Officer · last 29 May 20261 · 2
Jill M. Quigley Company insiderDirector · last 16 Jun 20230 · 0
Nissim Darvish Company insiderDirector · last 14 Jun 20231 · 0
Sigal Fatal Company insiderChief Financial Officer · last 14 Jun 20230 · 0
Alan Charles Moses Company insiderDirector · last 16 Mar 20230 · 0
Claude Nicaise Company insiderDirector · last 16 Mar 20230 · 0
Israel Biofund Gp Limited Partnership Orbimed Company insider10% owner · last 3 Jan 20230 · 1
Joel Michael Maryles Company insiderDirector · last 24 May 20222 · 0
Donald Marvin Company insiderExecutive VP, CFO & COO · last 16 Mar 20222 · 0
Dale R. Pfost Company insiderChief Executive Officer · last 14 Mar 20221 · 0
Stephen P. Squinto Company insiderDirector · last 19 Apr 20210 · 0

Same industry

MRNA ModernaLeading+154%
ENTX Entera BioLeading+49%
XNCR XencorLeading+32%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Earnings per share growthFY 2025 · to 31 Dec 2025-53.8%
Share count trendFY 2025 · to 31 Dec 202552.6%
Cash and equivalentsFY 2025 · to 31 Dec 2025$7.6M
Free cash flowFY 2025 · to 31 Dec 2025−$11.1M

Analyst forecasts

No analyst forecasts yet.